Instructions for Genferon Light (Taurine, Interferon Alfa 2b) 10 suppositories vaginal and rectal
Product name:
Genferone Light
Release form
vaginal and rectal supp. 125 000 IU+5 mg: 5 or 10 pcs
vaginal and rectal supp. 250 000 IU+5 mg: 5 or 10 pcs
Description:
Rectal and vaginal suppositories are white or white with a yellowish colour, cylindrical shape with a pointed end and homogenous on the longitudinal section; an air rod or a funnel depression is allowed on the section.
1 sp.
interferon alpha-2b 125,000 IU
taurin 5 mg
Auxiliary substances: Solid fat, dextran 60000, macrogol 1500, polysorbate 80, emulsifier T2, sodium hydrocitrate, citric acid, water purified - sufficient quantity until 0.8 g suppository.
5 pcs. - packages of box contour (1) - cardboard packs.
5 pcs. - packages of box contour (2) - cardboard packs.
ATC codes Taurine
L03A Immunostimulators
Clinical-pharmacological groups / Group affiliation
Interferon. Immunomodulating preparation with antiviral action
Active substance Genferon Light
taurin
interferon alpha-2b
Pharmacotherapy group
Immunomodulatory agent
Storage Conditions
At temperatures between 2 and 8°C. Store in a place not accessible to children.
Best before date
The shelf life is two years.
Testimony Genferon Light:
- as a component of the comprehensive therapy for the treatment of acute viral respiratory infections and other infectious
- diseases of bacterial and viral etiology in children;
- for the treatment of infection-inflammatory diseases of the urogenital tract in children and women,
- including pregnant women.
Method of use, course and dosage Genferon Light:
The preparation can be used both vaginally and rectally. The method of administration, dose and duration of the course depend on the age, specific clinical situation and are determined by the attending doctor.
In adults and children older than seven years, Genferon Light is used at a dose of 250,000 ME of interferon alpha-2b on the suppository. In children under seven years of age, it is safe to administer the drug at a dose of 125,000 ME of interferon alpha-2b on the suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 MEinterferon alpha-2b on the suppository.
Use in children
Applied according to indications
- Nosology Genferon Light (ICD codes)
- J00
- Acute nasopharyngitis
- J01
- Acute sinusitis
- J02
- Acute pharyngitis
- J03
- Acute tonsillitis
- J04
- Acute laryngitis and tracheitis
- J06.9
- Acute upper respiratory tract infection unspecified
- J10
- Influenza caused by an identified seasonal influenza virus
- J12
- Viral pneumonia not classified elsewhere
- J15
- Bacterial pneumonia not classified elsewhere
- J20
- Acute bronchitis
- J31
- Chronic rhinitis, nasopharyngitis and pharyngitis
- J32
- Chronic sinusitis
- J35.0
- Chronic tonsillitis
- J37
- Chronic laryngitis and laryngotracheitis
- J42
- Chronic bronchitis unspecified
- N34
- Urethritis and urethral syndrome
- N72
- Inflammatory disease of the cervix (incl. cervicite, endocervicite, exocervicite)
- N76
- Other inflammatory diseases of the vagina and vulva
Pharmacological effect Genferon Light:
Genferon Light is a combination drug, which is caused by the components in its composition. Has local and systemic effects. The preparation Genferon Light includes recombinant human interferon alpha-2b, produced by a bacterium strain Escherichia coli, in which the gene of human interferon alpha-2b is introduced by genetic engineering methods.
Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested primarily by the strengthening of cellular-mediated responses of the immune system, which increases the effectiveness of the immune response in relation to viruses, intracellular parasites and cells which have undergone a tumor transformation.
